A Novel Tetramethylpyrazine Chalcone Hybrid- HCTMPPK, as a Potential Anti-Lung Cancer Agent by Downregulating MELK
DOI: https://doi.org/10.2147/dddt.s449139
IF: 4.3188
2024-05-07
Drug Design Development and Therapy
Abstract:Yan Ma, 1, 2, &ast Qian Cui, 3, &ast Wenjing Zhu, 1, 4, &ast Mei Wang, 1, 2 Li Zhai, 5 Wenmin Hu, 1, 2 Dongdong Liu, 6 Min Liu, 5 Yongchun Li, 2 Meng Li, 2 Wei Han 1, 2 1 Qingdao Key Laboratory of Common Diseases, Qingdao Municipal Hospital, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong, 260071, People's Republic of China; 2 Department of Respiratory and Critical Care Medicine, Qingdao Municipal Hospital, University of Health and Rehabilitation Sciences, Qingdao, 266071, People's Republic of China; 3 Department of Respiratory and Critical Care Medicine, Shenzhen Luohu People's Hospital, Shenzhen, 518000, People's Republic of China; 4 NMPA Key Laboratory for Quality Research and Evaluation of Traditional Marine Chinese Medicine, Qingdao, 266071, People's Republic of China; 5 Department of Pharmacy, Qingdao Municipal Hospital, University of Health and Rehabilitation Sciences, Qingdao, 266071, People's Republic of China; 6 Department of Respiratory and Critical Care Medicine, Shanting District People's Hospital, Zaozhuang, 277200, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wei Han; Meng Li, Department of Respiratory and Critical Care Medicine, Qingdao Municipal Hospital, University of Health and Rehabilitation Sciences, Qingdao, 266071, People's Republic of China, Email ; Purpose: Lung adenocarcinoma currently ranks the leading causes of cancer-related mortality worldwide. Many anti-inflammation herbs, like tetramethylpyrazine, have shown their anti-tumor potentials. Here, we evaluated the role of a novel chalcone derivative of tetramethylpyrazine ((E) -1- (E) -1- (2-hydroxy-5-chlorophenyl) -3- (3,5,6-trimethylpyrazin-2-yl) -2-propen-1, HCTMPPK) in lung adenocarcinoma. Methods: The effects of HCTMPPK on cell proliferation, apoptosis, and invasion were investigated by in-vitro assays, including CCK-8, colony formation assay, flow cytometry, transwell assay, and wound-healing assay. The therapeutic potential of HCTMPPK in vivo was evaluated in xenograft mice. To figure out the target molecules of HCTMPPK, a network pharmacology approach and molecular docking studies were employed, and subsequent experiments were conducted to confirm these candidate molecules. Results: HCTMPPK effectively suppressed the proliferative activity and migration, as well as enhanced the apoptosis of A549 cells in a concentration-dependent manner. Consistent with this, tumor growth was inhibited by HCTMPPK significantly in vivo. Regarding the mechanisms, HCTMPPK down-regulated Bcl-2 and MMP-9 and up-regulating Bax and cleaved-caspase-3. Subsequently, we identified 601 overlapping DEGs from LUAD patients in TCGA and GEO database. Then, 15 hub genes were identified by PPI network and CytoHubba. Finally, MELK was verified to be the HCTMPPK targeted site, through the molecular docking studies and validation experiments. Conclusion: Overall, our study indicates HCTMPPK as a potential MELK inhibitor and may be a promising candidate for the therapy of lung cancer. Keywords: HCTMPPK((E) -1- (E) -1- (2-hydroxy-5-chlorophenyl) -3- (3,5,6-trimethylpyrazin-2-yl) -2-propen-1), chalcone, TMP, lung adenocarcinoma, network pharmacology, AutoDock Lung cancer is a highly lethal malignancy globally, 1 with non-small cell lung carcinoma (NSCLC) accounting for approximately 85% of all diagnosed cases. Despite this, the five-year survival rate for NSCLC is merely 15%. 2 Lung adenocarcinoma, which comprises approximately 40% of lung cancers, is the primary cause of morbidity and mortality in this context. 3 Most patients with lung cancer are typically diagnosed at an advanced or metastatic stage, and the primary therapeutic approach for NSCLC continues to involve a combination of surgical intervention and chemotherapy. 4–7 However, there are still many lung cancer patients who do not have an available immunotherapy regimen, do not have a specific molecular therapeutic target, and cannot tolerate the intense side effects of chemotherapy drugs. The therapeutic needs of these patients have prompted us to look for the development of novel, low-toxicity anticancer drugs from herbs that have some research basis. Therefore, it is crucial to discover new antineoplastic agents that are more selective towards malignant cells and less toxic to normal cells. The biologically active phytochemicals exhibit hypotoxic and pleiotropic properties, exerting interference on diverse cellular processes a -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal